Prof Ranjit Manchanda is Professor of Gynaecological Oncology at the Wolfson Institute of Preventive Medicine, Barts CRUK Cancer Centre, Queen Mary University of London, and Consultant Gynaecological Oncologist at Barts and the Royal London Hospital. 

Ranjit completed his PhD in Gynaecological Oncology at University College London (UCL). He completed a NIHR Clinical Academic Lectureship at UCL and speciality training in gynaecological oncology at University College London Hospital (UCLH) and St Bartholomew’s Hospital (Barts Health).

He is a NHS Innovation Accelerator (NIA) Fellow. He leads the high-risk women’s Precision Prevention service at Barts Health and is chair of the London Cancer High risk Gynaecological Cancer MDT. He is a member of the NCRI Ovarian Cancer Surgical Sub group. 

He has a keen interest in ultra-radical debulking surgery for ovarian cancer as well as minimal access surgery. He is a member of a number of advisory bodies and oversight committees. 

He is co-Lead for the Cancer Prevention Theme at the Barts CRUK Cancer Centre. He was recently appointed as Speciality Research Lead for Gynaecological Cancer, NIHR North Thames Clinical Research Network (CRN). He is the Integrated Academic Training Programme Director, London Speciality School of Obstetrics & Gynaecology, Health Education England. He is the Lead for the RCOG Advanced Professional Module (APM) in Clinical Research for North Central and North East London. 

He is a member of the International Gynecological Cancer Society (IGCS) Education Steering Committee and Deputy-Director of the Barts Health RCOG sub-speciality training programme in gynaecological oncology. He has led a number of training initiatives in Gynaecological Oncology across Europe. He has served as President of the European Network of Young Gynaecological Oncologists (ENYGO) and member of the European Society of Gynaecological Oncology (ESGO) Council from 2011 - 2013.

Ranjit’s research interests are focused around Targeted Precision Prevention. This includes population-based germline testing, mainstreaming and precision medicine approaches for risk prediction, stratification, and targeted screening & cancer prevention. 

He has a keen research interest in health economic issues related to his areas of research. He was awarded a NIA Fellowship for Population Genetic Testing. He is the Chief Investigator of a number of studies, including, the PROTECTOR trial, PROMISE Pilot study, GCaPPS trial, RRESDO and SIGNPOST study. 

He serves on the editorial board of important scientific journals and has lectured and published widely on topics related to his academic and clinical work.

• Management of high risk women, e.g. BRCA, Lynch Syndrome, Cowden's syndrome, RAD51C, RAD51D, BRIP1, PALB2
• Genetic testing - gynaecological cancers
• Cancer risk assessment (gynaecological cancers)

• Professor of Gynaecological Oncology
  Wolfson Institute of Preventive Medicine, Barts Cancer Research UK Centre, Queen Mary University of London
• Consultant Gynaecological Oncologist
  Barts Health NHS Trust, Royal London Hospital
• NHS Innovation Accelerator (NIA) Fellow
  NHS Innovation Accelerator

• Integrated Academic Training Programme Director, Obstetrics & Gynaecology
  London School of Obstetrics & Gynaecology (LSSOG), Health Education England (HEE)
• Deputy Director Sub-speciality Training Programme, Gynaecological Oncology
  Barts Health NHS Trust

Professor Manchanda is the recipient of a number of awards, including:

• Shyam Agarwal Memorial Oration Award (Dec 2019)
• NHS Innovation Accelerator Fellowship Award (Mar 2019)
• Local Clinical Excellence Award (2019)
• William Blair Bell Memorial Lecture Award (RCOG, 2018)
• Helen Harris Memorial Trust Travelling Fellowship Award (2011)
• NIHR Academic Clinical Lecturer award (2010)
• Indian Council of Medical Research (ICMR) Fellowship award (2000 - 2001)

• All India Institute of Medical Sciences (AIIMS), New Delhi, India